KHN702
Phase 1Small molecule
KHN702 is one of 48 small molecule programs targeting Post Operative Pain. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
64 competitors in Post Operative Pain
#DrugCompanyPhaseTrials
1Marcaine
IInnocoll
Approved
Advil
KKenvue Brands
Approved
Duragesic
CCephalon
Approved
Oxycontin
PProtega
Approved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Suboxone
IIndivior Inc.
Approved
Achromycin V
WWyeth-Lederle Vaccines
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Cyklokapron
JJ Molner
Phase 3
Bupivacain
IIstanbul University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KHN702. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details